Methods for use with BAFF antagonists
View Patent ↗BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample.
1. A method for monitoring efficacy of an antagonist to BAFF (SEQ ID NO:30) in a human, comprising the steps of administering the BAFF antagonist to the human, obtaining from the human a biological sample comprising B cells, and detecting a level in the biological sample of one or more molecules selected from the group consisting of:
(a) a polypeptide comprising a sequence selected from SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18; and
(b) an mRNA comprising a nucleotide sequence encoding an amino acid sequence selected from SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18,
wherein the level, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist in the human, and wherein the BAFF antagonist inhibits the interaction between BAFF and a BAFF receptor and is selected from the group consisting of an anti-BAFF antibody, an anti-BAFF-R antibody, and a BAFF-R-Fc polypeptide.
2. The method for monitoring efficacy of a BAFF antagonist in a human according to claim 1 , wherein the method further comprises the step of detecting a level in the biological sample of one or more molecules selected from the group consisting of
(a) a polypeptide comprising a sequence selected from SEQ ID NO:19 and SEQ ID NO:20; and
(b) an mRNA encoding an amino acid sequence selected from SEQ ID NO:19 and SEQ ID NO:20;
wherein the level, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist in the human.
3. The method according to claim 1 , wherein the human is suffering from an autoimmune disease.
4. The method according to claim 3 , wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, lupus, and Sjogren's disease.
5. The method for monitoring efficacy of a BAFF antagonist in a human according to claim 1 , further comprising the step of detecting a level in the biological sample of at least one molecule selected from the group consisting of BAFF (SEQ ID NO:30) and an mRNA encoding BAFF, wherein the level, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist in the human.
6. The method for monitoring efficacy of a BAFF antagonist in a human according to claim 1 , further comprising the step of detecting a level in the biological sample of at least one molecule selected from the group consisting of BAFF-R (SEQ ID NO:23) and an mRNA encoding BAFF-R, wherein the level, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist human.
7. The method according to a claim 1 , wherein the molecule is a polypeptide comprising the sequence of SEQ ID NO:16 or an mRNA comprising a sequence encoding SEQ ID NO:16.